Welcome to our dedicated page for Oxford Immunotec news (Ticker: OXFD), a resource for investors and traders seeking the latest updates and insights on Oxford Immunotec stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oxford Immunotec's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oxford Immunotec's position in the market.
Oxford Immunotec reported a Q1 2020 revenue of $13.9 million, down 6% from $14.8 million in Q1 2019, primarily due to COVID-19 impacts in China. Gross margins improved to 74%, up 270bps year-over-year. The company ended the quarter with $166 million in cash. Notably, U.S. revenues rose by 4% to $5.7 million, while Asia saw a 22% decline. The company anticipates Q2 revenues to range between $5 million and $6 million, predicting it to be the lowest quarter of the year.
Summary not available.